Predicting Infections In Cancer Of The Plasma Cells In Bone Marrow (myeloma)
Funder
National Health and Medical Research Council
Funding Amount
$107,764.00
Summary
The study will look for new risks for infection in patients with multiple myeloma, a cancer of plasma cells in the bone marrow. Currently these patients are expected to live longer because of the discovery and use of new generation cancer drugs. By finding new infection risks, the treatment of life threatening infections can be improved or infection can be prevented so patients have a better quality of life whilst on cancer treatment.
Does Teriparatide Reverse Osteonecrosis Of The Jaw In Patients With Cancer? A Randomised, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Osteonecrosis of the jaw (ONJ) is a debilitating bone condition involving damage and suboptimal healing of bone involving the jaw. This has been associated with bisphosphonate therapy, which is commonly used for the treatment of both cancer and osteoporosis. My research aims to investigate the role of recombinant parathyroid hormone in the stimulation of bone formation and healing and, thus, its potential to reverse ONJ.
Vitamin D And Genetic Susceptibility In Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Vitamin D3 levels appear to predict clinical status in multiple sclerosis. The reasons for this are unclear, but may be linked to the effect of the Vitamin D Receptor (VDR) on a subset of immune cells. This project aims to identify key genes which are regulated by this receptor, by using specific gene sequencing technologies combined with knowledge of the genes which confer risk of developing MS. This may help to identify the molecular pathways underlying MS and potential treatment strategies.
Determining The Mechanisms Of Tolerance After Autologous Stem Cell Transplantation For Multiple Sclerosis – The Role Of CD39+ T Regulatory Cells
Funder
National Health and Medical Research Council
Funding Amount
$86,117.00
Summary
Autologous haematopoietic stem cell transplant offers relief for patients with aggressive forms of autoimmune diseases such as multiple sclerosis. Here, we aim to understand how this therapy relieves symptoms in multiple sclerosis patients by studying the biology of CD39+ T regulatory cells. Understanding these immune-suppressing cells can lead to the development of new transplant procedures without chemotherapy and ultimately improve transplant outcomes for autoimmune disease patients.
Environmental Risk Factors For Primary Progressive Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$86,118.00
Summary
Primary Progressive Multiple Sclerosis (PPMS) is a form of MS affecting 10% of people with the disease. PPMS has been less researched than the more common form of MS, Relapsing Remitting MS (RRMS), and unlike RRMS, there are currently no effective treatments. This project will examine whether the established risk factors for RRMS also hold for PPMS, whether the magnitude of risk associated with these factors is the same for PPMS, and whether novel risk factors for PPMS can be identified.
How Does Fampridine Affect Upper Limb Function In Multiple Sclerosis?
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.